Divergent roles for p55 and p75 TNF-α receptors in the induction of plasminogen activator inhibitor-1

American Journal of Pathology

Volumn 162, Issue 3, 2003, Pages 933-941

  Pandey, Manjula ^a   Tuncman, Gurol ^b   Hotamisligil, Gökhan S ^b   Samad, Fahumiya ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P55; PROTEIN P57; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADIPOSE TISSUE; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE INDUCTION; HEART; INFLAMMATION; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RECEPTOR INTRINSIC ACTIVITY;

EID: 0345505667     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63888-6     Document Type: Article

References (82)

1. Beutler B, Cerami A: The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol 1989, 7:625-655
2. Barbara JA, van ostade X, Lopez A: Tumor necrosis factor-α (TNF-α): the good, the bad and potentially very effective. Immunol Cell Biol 1996, 74:434-443
3. Sethi JK, Hotamisligil GS: The role of TNFα in adipocyte metabolism. Cell Dev Biol 1999, 10:19-29
4. Wajant H, Pfeffer K, Pfizenmaier K, Scheurich P: Tumor necrosis factors in 1998. Cytokine Growth Factor Rev 1998, 9:297-302
5. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997, 385:729-733
6. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997, 385:733-736
7. Grell M: Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflam 1995, 47:8-17
8. Decoster E, Vanhaesebroeck B, Vandenabeele P, Grooten J, Fiers W: Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J Biol Chem 1995, 31:18473-18478
9. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 KDa tumor necrosis factor receptor. Cell 1995, 83:793-802
10. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990, 63:251-258
11. Probert L, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Kollias G: Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. J Leukoc Biol 1996, 59:518-525
12. Mueller C, Corazza N, Trachsel-Loseth S, Eugster HP, Buhler-Jungo M, Brunner T, Imboden MA: Noncleavable transmembrane mouse tumor necrosis factor-α (TNFα) mediates effects distinct from those of wild-type TNF-α in vitro and in vivo. J Biol Chem 1999, 274:38112-38118
13. Bazzoni F, Beutler B: How do tumor necrosis factor receptors work? J Inflam 1995, 45:221-238
14. Vandenabeele P, Declercq W, Beyaert R, Fiers W: Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995, 5:392-399
15. Rothe J, Gehr G, Loetscher H, Lesslauer W: Tumor necrosis factor receptors: structure and function. Immunol Res 1992, 11:81-90
16. Bigda J, Holtmann H: TNF receptors: how they function and interact. Arch Immunol Ther Exp 1997, 45:263-270
17. Solomon KA, Pesti N, Wu G, Newton RC: Cutting edge: a dominant negative form of TNF-α converting enzyme inhibits proTNF and TN-FRII secretion. J Immunol 1999, 163:4105-4108
18. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF: A metalloprotease inhibitor blocks shedding of 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995, 181:1205-1210
19. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD: Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 1995, 181:607-617
20. Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T: Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 1990, 172:1517-1520
21. Liu LS, Spelleken M, Röhrig K, Hauner H, Eckel J: Tumor necrosis factor-α acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes 1998, 47:515-522
22. Clauss M, Grell M, Fangmann C, Fiers W, Scheurich P, Risau W: Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors. FEBS Lett 1996, 390:334-338
23. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W: Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993. 177:1277-1286
24. van der Poll T, Jansen PM, Van Zee KJ, Welborn MB3, de Jong I, Hack CE, Loetscher H, Lesslauer W, Lowry SF, Moldawer LL: Tumor necrosis factor-α induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 1996, 88:922-927
25. Hube F, Hauner H: The two tumor necrosis factor receptors mediate opposite effects on differentiation and glucose metabolism in human adipocytes in primary culture. Endocrinol 2000, 141:2582-2588
26. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997, 389:610-614
27. Xu H, Sethi JK, Hotamisligil GS: Transmembrane tumor necrosis factor (TNF)-α inhibits adipocyte differentiation by selectively activating TNF receptor 1. J Biol Chem 1999, 274:26287-26295
28. Kalb A, Bluethmann H, Moore MW, Lesslauer W: Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics. J Biol Chem 1996, 271:28097-28104
29. Uysal KT, Wiesbrock SM, Hotamisligil GS: Functional analysis of tumor necrosis factor (TNF) receptors in TNF-α-mediated insulin resistance in genetic obesity. Endocrinol 1998, 139:4832-4838
30. Sethi JK, Xu H, Uysal KT, Wiesbrock SM, Scheja L, Hotamisligil GS: Characterisation of receptor-specific TNFα functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett 2000, 469:77-82
31. Yamada Y, Kirillova I, Peschon JJ, Fausto N: Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997, 94:1441-1446
32. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73:457-467
33. Tartaglia LA, Rothe M, Hu YF, Goeddel DV: Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 1993, 73:213-216
34. Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H: Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364:798-802
35. Pasparakis M, Alexopoulou L, Grell M, Pfizenmaier K, Bluethmann H, Kollias G: Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc Natl Acad Sci USA 1997, 94:6319-6323
36. Rink L, Kirchner H: Recent progress in the tumor necrosis factor-α field. Int Arch Allergy Immunol 1996, 111:199-209
37. Erickson SL, De Sauvage F, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KCF, Schreiber RD, Goeddel DV, Moore MW: Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994, 372:560-563
38. Wang B, Fujisawa H, Zhuang L, Kondo S, Shivji GM, Kim CS, Mak TW, Sauder DN: Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75. J Immunol 1997, 159:6148-6155
39. Lucas R, Juillard P, Decoster E, Redard M, Burger D, Donati Y, Giroud C, Monso-Hinard C, De Kesel T, Buurman WA, Moore MW, Dayer JM, Fiers W, Bluethmann H, Grau GE: Crucial role of tumor necrsosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 1997, 27:1719-1725
40. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377:348-351
41. Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, Palladino Jr MA: Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor. J Immunol 1993, 151:4637-4641
42. Rao P, Hsu KC, Chao MV: Up-regulation of NF-κ B-dependent gene expression mediated by the p75 tumor necrosis factor receptor. J Interferon Cytokine Res 1995, 15:171-177
43. Samad F, Yamamoto K, Pandey M, Loskutoff D: Elevated expression of transforming growth factor-β in adipose tissue from obese mice. Mol Med 1997, 3:37-48
44. Samad F, Yamamoto K, Loskutoff DJ: Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 1996, 97:37-46
45. Fearns C, Samad F, Loskutoff DJ: Synthesis and localization of PAI-1 in the vessel wall. Vascular Control of Hemostasis. Edited by van Hinsbergh VWM. Amsterdam, The Netherlands, Harwood Academic Publishers, 1995, pp 207-226
46. Noël A, Bajou K, Masson V, Devy L, Frankenne F, Rakic JM, Lambert V, Carmeliet P, Foidart JM: Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis Proteolysis 1999; 13:220-225
47. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noël A, Foidart J-M: The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. EMBO J 2002, 16:47-154
48. Loskutoff DJ: PAI-1 inhibits neointimal formation after arterial injury in mice: a new target for controlling restenosis? Circulation 1997, 96:2772-2774
49. Deng G, Curriden SA, Hu G, Czekay R-P, Loskutoff DJ: Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronect. J Cell Physiol 2001, 189:23-33
50. Huber K, Christ G, Wojta J, Gulba D: Plasminogen activator inhibitor type-1 in cardiovascular disease: status report 2001. Thromb Res 2001, 103:S7-S19
51. Nordt TK, Peter K, Ruef J, Kubler W, Bode C: Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999, 82:14-18
52. Westendorp RG, Hottenga JJ, Slagboom PE: Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999, 354:561-563
53. Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann FW: Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987, 69:460-466
54. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994, 43:104-109
55. Juhan-Vague I, Alessi MC: PAI-1, obesity, insulin resistance, and risk of cardiovascular events. Thromb Haemost 1997, 78:656-660
56. Legnani C, Maccaferri M, Tonini P, Cassio A, Cacciari E, Coccheri S: Reduced fibrinolytic response in obese children: association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1). Fibrinolysis 1988, 2:211-214
57. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993, 42:945-949
58. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ: Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor-1. Proc Natl Acad Sci USA 1999, 96:6902-6907
59. Schleef RR, Sinha M, Loskutoff DJ: Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. J Lab Clin Med 1985, 106:408-415
60. Samad F, Loskutoff DJ: Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996, 2:568-582
61. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415
62. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994, 43:1271-1278
63. Peraldi P, Spiegelman B: TNF-α and insulin resistance: summary and future prospects. Mol Cell Biochem 1998, 182:169-175
64. Hube F, Hauner H: The role of TNF-α in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999, 31:626-631
65. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino Jr MA, Goeddel DV: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991, 88:9292-9296
66. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV: A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74:845-853
67. Bastelca D, Mavri A, Verdier M, Berthet B, Juhan-Vague I, Alessi M-C: Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFα receptors to PAI-1 levels. Thromb Haemost 2002, 88:481-487
68. Schmid EF, Binder K, Grell M, Scheurich P, Pfizenmaier K: Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor α. Blood 1995, 86:1836-1841
69. Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil G: Altered tumor necrosis factor-α (TNF-α) processing in adipocytes and increased expression of transmembrane TNFα in obesity. Diabetes 2002, 51:1876-1883
70. Alexopoulou L, Pasparakis M, Kollias G: A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997, 27:2588-2592
71. Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kunstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G, Grell M: In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997, 2870-2875
72. Pinckard JK, Sheehan KCF, Schreiber RD: Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 1997, 272;10784-10789
73. Carpenter A, Evans TJ, Buurman WA, Bemelmans MH, Moyes D, Cohen J: Differences in the shedding of soluble TNF receptors between endotoxin-sensitive and endotoxin-resistant mice in response to lipopolysaccharide or live bacterial challenge. J Immunol 1995, 155:2005-2012
74. Aderka D: The potential biologial and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996, 7:231-240
75. McFadden G, Graham K, Ellison K, Barry M, Macen J, Schreiber M, Mossman K, Nash P, Lalani A, Everett H: Interruption of cytokine networks by poxviruses: lessons from myxoma virus. J Leukoc Biol 1995, 57:731-738
76. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet PF, Pointaire P, Vassalli P, Loetscher H: Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991, 21:2883-2886
77. Hunger RE, Carnaud C, Garcia I, Vassalli P, Mueller C: Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis. Eur J Immunol 1997, 27:255-261
78. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151:1548-1561
79. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993, 151:6602-6607
80. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91
81. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175:323-329
82. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM: TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998, 160:943-952